Guided Therapeutics (GTHP) stock price, revenue, and financials

Guided Therapeutics market cap is $4.7 m, and annual revenue was $36 k in FY 2019

$4.7 M

GTHP Mkt cap, 23-Sept-2020
Guided Therapeutics Gross profit (Q2, 2020)-6 K
Guided Therapeutics Net income (Q2, 2020)-6.7 M
Guided Therapeutics EBIT (Q2, 2020)-369 K
Guided Therapeutics Cash, 30-Jun-2020763 K
Guided Therapeutics EV5 M

Guided Therapeutics Income Statement

Quarterly

USDQ2, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

913.0k718.0k915.0k693.0k167.0k222.0k86.0k19.0k11.0k22.0k15.0k10.0k8.0k33.0k4.0k8.0k2.0k18.0k1.0k

Cost of goods sold

75.0k55.0k158.0k119.0k117.0k192.0k271.0k260.0k107.0k207.0k230.0k68.0k33.0k85.0k16.0k82.0k97.0k3.0k1.0k1.0k65.0k6.0k

Gross profit

840.0k638.0k9.0k103.0k(31.0k)(173.0k)(260.0k)(238.0k)(92.0k)(197.0k)(222.0k)(64.0k)1.0k7.0k2.0k17.0k(64.0k)(6.0k)

Gross profit Margin, %

92%92%5%46%(36%)(911%)(2364%)(1082%)(613%)(1970%)(2775%)(194%)25%88%100%94%(6400%)

Sales and marketing expense

71.0k70.0k69.0k132.0k164.0k195.0k249.0k283.0k345.0k135.0k172.0k183.0k187.0k117.0k86.0k92.0k82.0k67.0k37.0k62.0k55.0k39.0k45.0k31.0k15.0k34.0k37.0k

R&D expense

619.0k714.0k898.0k787.0k813.0k834.0k596.0k607.0k624.0k892.0k373.0k305.0k413.0k290.0k148.0k87.0k91.0k89.0k69.0k69.0k62.0k43.0k47.0k43.0k23.0k24.0k55.0k

General and administrative expense

708.0k930.0k1.1m732.0k1.0m931.0k822.0k1.1m999.0k1.4m963.0k1.0m1.1m917.0k760.0k510.0k346.0k382.0k1.2m246.0k381.0k154.0k182.0k189.0k151.0k184.0k271.0k

Operating expense total

1.4m1.7m1.1m958.0k1.8m1.7m1.6m2.0m2.0m2.4m1.5m1.5m1.7m1.3m994.0k689.0k519.0k538.0k1.3m377.0k498.0k236.0k274.0k263.0k189.0k242.0k363.0k

EBIT

(485.0k)(996.0k)(1.1m)(970.0k)(1.9m)(1.7m)(1.6m)(2.1m)(2.0m)(2.4m)(1.5m)(1.6m)(1.8m)(1.1m)(898.0k)(679.0k)(514.0k)(533.0k)(1.3m)(376.0k)(491.0k)(234.0k)(257.0k)(327.0k)(188.0k)(242.0k)(369.0k)

EBIT margin, %

(53%)(139%)(125%)(140%)(1123%)(784%)(1907%)(10942%)(18427%)(10977%)(9820%)(16010%)(22975%)(4058%)(9400%)(6137%)(11700%)(1428%)(32700%)

Interest expense

18.0k17.0k19.0k16.0k15.0k9.0k323.0k69.0k

Interest income

228.0k105.0k353.0k1.3m981.0k

Pre tax profit

(1.7m)(1.7m)(2.2m)130.0k(1.9m)(211.0k)(107.0k)(1.1m)(2.4m)1.1m3.4m(746.0k)(215.0k)(2.7m)(126.0k)2.7m(6.7m)

Net Income

(496.0k)(1.0m)(1.2m)(986.0k)(1.8m)(1.7m)(1.4m)(1.6m)(2.2m)(3.0m)(1.2m)(1.7m)(2.2m)130.0k(1.9m)(211.0k)(107.0k)(1.1m)(2.4m)1.1m3.4m(746.0k)(215.0k)(2.7m)(126.0k)2.7m(6.7m)

Guided Therapeutics Balance Sheet

Quarterly

USDQ2, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

2.3m1.0m1.4m2.6m1.1m2.0m400.0k50.0k485.0k42.0k18.0k2.0m172.0k56.0k22.0k4.0k1.0k8.0k74.0k76.0k41.0k70.0k6.0k21.0k763.0k

Accounts Receivable

149.0k38.0k139.0k65.0k166.0k177.0k112.0k122.0k233.0k417.0k358.0k282.0k219.0k230.0k289.0k226.0k41.0k4.0k5.0k6.0k4.0k13.0k16.0k14.0k24.0k

Prepaid Expenses

22.0k45.0k39.0k119.0k247.0k115.0k185.0k48.0k13.0k431.0k52.0k28.0k979.0k509.0k502.0k463.0k206.0k356.0k179.0k90.0k41.0k108.0k36.0k2.0k

Inventories

64.0k459.0k461.1k439.0607.044.0k120.0k1.1m1.2m1.1m985.0k912.0k1.3m1.2m1.2m836.0k756.0k577.0k295.0k280.0k265.0k112.0k48.0k48.0k57.0k51.0k

Current Assets

2.5m1.7m2.1m3.3m2.0m2.9m1.5m1.5m1.9m2.1m1.6m3.3m2.3m2.0m2.1m1.9m1.1m1.1m830.0k466.0k368.0k447.0k167.0k66.0k168.0k238.0k855.0k

PP&E

64.0k1.1m1.2m1.3m1.3m1.1m1.0m807.0k804.0k706.0k515.0k444.0k377.0k264.0k217.0k171.0k89.0k65.0k56.0k43.0k32.0k27.0k16.0k1.0k

Total Assets

3.3m3.1m3.5m4.8m3.6m4.4m2.9m2.6m3.8m3.7m2.6m4.0m2.8m2.4m2.3m2.1m1.5m1.5m905.0k527.0k418.0k491.0k404.0k260.0k339.0k364.0k942.0k

Accounts Payable

937.0k863.0k1.1m1.0m878.0k986.0k822.0k1.3m1.1m1.7m1.6m2.0m1.5m2.0m2.2m2.5m2.7m2.9m3.0m3.0m3.0m3.0m3.0m2.9m3.0m2.8m2.8m

Dividends Payable

132.0k

Short-term debt

24.0k24.0k17.0k11.0k100.0k101.0k107.0k111.0k160.0k118.0k168.0k679.0k3.9m839.0k518.0k

Current Liabilities

2.9m2.2m3.1m2.6m1.5m1.6m1.6m2.8m2.5m4.1m5.2m4.8m5.0m6.0m8.0m8.5m9.7m10.8m11.4m12.2m12.6m10.7m11.7m11.7m11.6m9.2m8.6m

Long-term debt

17.0k1.7m157.0k135.0k99.0k4.0k40.0k1.0m405.0k72.0k66.0k221.0k575.0k

Non-Current Liabilities

1.0m798.0k1.1m3.8m3.5m2.4m2.0m1.3m1.8m4.0m4.7m7.1m6.7m2.5m8.7m

Total Debt

41.0k24.0k17.0k11.0k1.8m258.0k242.0k210.0k164.0k158.0k168.0k1.0m585.0k814.0k905.0k973.0k1.0m445.0k751.0k4.0m1.1m1.1m

Total Liabilities

2.9m2.2m3.1m2.6m2.4m3.9m6.3m7.7m7.6m6.8m6.3m7.8m9.4m9.4m10.5m11.9m13.3m18.5m14.6m14.7m16.4m18.8m18.4m11.7m17.4m

Common Stock

48.0k53.0k56.0k62.0k66.0k66.0k66.0k72.0k75.0k79.0k99.0k112.0k143.0k297.0k376.0k600.0k743.0k744.0k751.0k879.0k1.0m1.1m3.4m3.4m3.4m3.4m3.4m

Preferred Stock

1.3m

Additional Paid-in Capital

80.0m87.0m87.9m93.0m95.8m97.3m97.6m102.5m103.6m105.3m108.7m113.0m114.5m115.5m116.2m116.3m116.9m116.8m117.2m117.9m118.2m118.9m117.8m117.9m118.6m121.2m122.0m

Retained Earnings

(79.7m)(86.1m)(87.5m)(90.9m)(93.9m)(96.8m)(98.3m)(104.6m)(106.8m)(109.8m)(114.3m)(117.3m)(120.1m)(122.9m)(125.1m)(125.5m)(127.8m)(128.9m)(131.3m)(137.5m)(134.1m)(134.9m)(137.9m)(140.5m)(140.6m)(136.8m)(143.6m)

Total Equity

410.0k908.0k438.0k2.1m1.9m1.7m522.0k(1.3m)(2.5m)(3.9m)(5.0m)(2.7m)(3.5m)(5.4m)(7.1m)(7.3m)(9.1m)(10.3m)(12.3m)(17.9m)(14.2m)(14.2m)(16.0m)(18.6m)(18.0m)(11.3m)(16.4m)

Debt to Equity Ratio

0.1 x0 x0 x0 x1 x0.1 x0.5 x-0.2 x-0.1 x0 x0 x-0.4 x-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x0.5 x0.1 x0.1 x0.1 x0 x0 x0.1 x0.3 x0.4 x0.9 x1.7 x2.3 x2.1 x1.1 x

Financial Leverage

8.1 x3.4 x8 x2.2 x1.9 x2.5 x5.6 x-2 x-1.5 x-0.9 x-0.5 x-1.5 x-0.8 x-0.4 x-0.3 x-0.3 x-0.2 x-0.1 x-0.1 x0 x0 x0 x0 x0 x0 x0 x-0.1 x

Guided Therapeutics Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(6.6m)(4.4m)(7.2m)(9.9m)(6.9m)(4.0m)(10.7m)1.0m(1.9m)

Depreciation and Amortization

34.0k361.0k461.0k1.2m1.1m1.2m213.0k27.0k21.0k

Accounts Receivable

50.0k(13.0k)33.0k(267.0k)129.0k(31.0k)(9.0k)(10.0k)

Inventories

520.0k4.0k669.0k14.0k61.0k345.0k508.0k151.0k66.0k

Accounts Payable

187.0k(337.0k)126.0k842.0k91.0k775.0k420.0k(6.0k)20.0k

Cash From Operating Activities

(1.1m)(1.4m)(806.0k)

Purchases of PP&E

Cash From Investing Activities

(704.0k)(552.0k)(107.0k)(150.0k)(8.0k)

Dividends Paid

(104.0k)

Cash From Financing Activities

2.4m3.1m5.2m6.0m3.9m1.8m1.1m1.4m1.7m

Net Change in Cash

(1.1m)(1.2m)(432.0k)(451.0k)(127.0k)(21.0k)(13.0k)(1.0k)899.0k

Interest Paid

183.0k48.0k31.0k33.0k76.0k46.0k116.0k14.0k

Income Taxes Paid

Quarterly

USDQ2, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(496.0k)(1.0m)(2.2m)(3.2m)(1.8m)(3.6m)(5.0m)(1.6m)(3.7m)(6.7m)(1.2m)(3.0m)(5.1m)130.0k(1.7m)(2.0m)(107.0k)(1.2m)(3.5m)1.1m4.5m3.8m(215.0k)(2.9m)(3.0m)2.7m(4.0m)

Depreciation and Amortization

75.0k163.0k258.0k112.0k227.0k344.0k117.0k300.0k359.0k474.0k687.0k990.0k54.0k918.0k1.1m37.0k188.0k273.0k58.0k113.0k171.0k42.0k75.0k94.0k19.0k53.0k

Accounts Receivable

(96.0k)14.0k(59.0k)65.0k76.0k11.0k(11.0k)100.0k316.0k31.0k56.0k119.0k(56.0k)(119.0k)(53.0k)(6.0k)31.0k(89.0k)(2.0k)(3.0k)(1.0k)(3.0k)(1.0k)(11.0k)

Inventories

88.0k(61.0k)(60.0k)(85.0k)94.0k296.0k61.0k74.0k(11.0k)(20.0k)194.0k268.0k(135.0k)(120.0k)(40.0k)(63.0k)17.0k196.0k(30.0k)(14.0k)1.0k2.0k66.0k66.0k(9.0k)(3.0k)

Accounts Payable

(239.0k)(33.0k)(62.0k)113.0k221.0k57.0k377.0k172.0k774.0k(169.0k)231.0k(267.0k)153.0k384.0k626.0k148.0k288.0k366.0k(45.0k)(60.0k)(48.0k)(9.0k)29.0k62.0k(67.0k)19.0k

Cash From Operating Activities

(481.0k)(395.0k)(637.0k)(1.1m)(186.0k)(374.0k)(602.0k)(530.0k)(938.0k)

Purchases of PP&E

(101.0k)(111.0k)(4.0k)(119.0k)(144.0k)(2.0k)(1.0k)

Cash From Investing Activities

(130.0k)(351.0k)(496.0k)(101.0k)(101.0k)(111.0k)(4.0k)(119.0k)(144.0k)(2.0k)(1.0k)

Short-term Borrowings

(91.0k)(38.0k)(100.0k)(146.0k)(451.0k)(697.0k)

Cash From Financing Activities

124.0k679.0k3.0m1.5m3.8m3.9m400.0k2.8m4.4m482.0k3.0m3.6m976.0k1.5m1.6m394.0k271.0k541.0k470.0k677.0k1.1m192.0k374.0k602.0k(348.0k)803.0k

Net Change in Cash

(1.2m)(760.0k)409.0k65.0k936.0k(644.0k)(563.0k)(128.0k)(571.0k)(144.0k)1.8m10.0k21.0k(13.0k)(31.0k)(13.0k)(6.0k)60.0k75.0k40.0k69.0k6.0k(878.0k)(136.0k)

Interest Paid

5.0k11.0k12.0k4.0k9.0k11.0k8.0k20.0k33.0k22.0k56.0k76.0k1.0k1.0k62.0k1.0k1.0k1.0k69.0k115.0k116.0k165.0k209.0k

Guided Therapeutics Ratios

USDQ2, 2011

Debt/Equity

0.1 x

Financial Leverage

8.1 x